“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Se muestra el contenido original; la traduccion localizada aun no esta disponible.
Qué ocurrió
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Por que importa
The development may change operating conditions or market expectations around AI. Further confirmation and measurable outcomes matter.
Entidades afectadas
Ver evidencia
1 articulos · 1 informe original · 1 independientes
- TechCrunch AIFuente primaria · Respalda · EN · 100%“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z ↗
Afirmaciones
- “We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z Observado
Conflictos
No se detectaron conflictos importantes en la evidencia disponible.
Cronología
- Primera publicación
Movimiento del mercado posterior al evento
La reacción del mercado aún no está disponible para este activo y periodo.